|1.||Bresnick, Anne R: 5 articles (08/2011 - 05/2006)|
|2.||Chandran, Bala: 4 articles (02/2014 - 01/2010)|
|3.||Chakraborty, Sayan: 4 articles (02/2014 - 01/2010)|
|4.||Pecci, Alessandro: 4 articles (08/2012 - 01/2003)|
|5.||Savoia, Anna: 3 articles (08/2012 - 01/2003)|
|6.||Balduini, Carlo L: 3 articles (10/2011 - 01/2003)|
|7.||Dulyaninova, Natalya G: 3 articles (08/2011 - 08/2007)|
|8.||Weber, David J: 3 articles (08/2011 - 05/2008)|
|9.||Cota, Ernesto: 2 articles (01/2015 - 03/2010)|
|10.||Tate, Edward W: 2 articles (01/2015 - 03/2010)|
02/12/2008 - "Cases of adenocarcinoma lacking expression of either myosin IIA or vimentin show a good outcome without PAC, and therefore do not require such treatment."
02/01/2011 - "We report that MDA-MB-231 human breast adenocarcinoma cells invade 3D Matrigel with a characteristic rounded morphology and with F-actin and myosin-IIa accumulating at the cell rear in a uropod-like structure. "
02/12/2008 - "Furthermore, we carried out immunohistochemical studies of 90 adenocarcinoma specimens to validate the results of LC-MS/MS. We detected two kinds of protein molecules (myosin IIA and vimentin) by LC-MS/MS. We confirmed their immunohistochemical expression and distribution, and evaluated the relationship between the expression of these proteins and prognosis after adjuvant chemotherapy. "
11/09/2012 - "We previously found that myosin binding protein H (MYBPH) is directly transactivated by the TTF-1 lineage-survival oncogene in lung adenocarcinomas and inhibits phosphorylation of the myosin regulatory light chain (RLC) of non-muscle myosin IIA (NM IIA) via direct interaction with Rho kinase 1 (ROCK1). "
|2.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/01/2010 - "This is the first study demonstrating the role of c-Cbl in viral entry as well as macropinocytosis, and provides the evidence that a signaling complex containing c-Cbl and myosin IIA plays a crucial role in blebbing and macropinocytosis during viral infection and suggests that targeting c-Cbl could lead to a block in KSHV infection."
02/01/2014 - "Mass spectrometry revealed the simultaneous association of CIB1 and EphA2 with the actin cytoskeleton modulating myosin IIA and alpha-actinin 4 molecules, and CIB1 knockdown reduced EphA2's association with myosin IIA and alpha-actinin 4. Collectively, these studies revealed for the first time that CIB1 plays a role in virus entry and macropinocytosis, and suggested that KSHV utilizes CIB1 as one of the key molecule(s) to coordinate and sustain the EphA2 mediated signaling involved in its entry, and CIB1 is an attractive therapeutic target to block KSHV infection. "
07/01/2010 - "parvum infection of cultured cholangiocytes results in the localized selective aggregation of myosin IIB but not myosin IIA at the region of parasite attachment, as assessed by dual-label immunofluorescence confocal microscopy. "
01/01/2015 - "Myosin A, actin, aldolase, and thrombospondin-related anonymous protein (TRAP) constitute the molecular core of the glideosome in the sporozoite, the mosquito stage that brings the infection into mammals. "
01/01/2010 - "Studies with the myosin II inhibitor blebbistatin demonstrated that myosin IIA is a biologically significant component of the c-Cbl signaling pathway and c-Cbl plays a new role in the recruitment of myosin IIA to the blebs during KSHV infection. "
07/01/2012 - "In this study, we investigate the expression level of myosin IIA in 50 esophageal squamous cancer and 30 adjacent normal esophageal tissues by immunohistochemical staining and correlated its expression with clinicopathological features. "
06/15/2015 - "Furthermore, we show that inhibition or silencing of myosin IIa enhances aggregation, suggesting that cytoskeleton tension inhibits tumor cell aggregation. "
03/01/2014 - "An in vivo RNAi screen identified nonmuscle myosin IIa (MYH9) as a tumor suppressor in SCC. "
01/17/2014 - "Myosin IIa is diminished in human SCCs with poor survival, which suggests that in vivo RNAi technology might be useful for identifying potent but low-penetrance tumor suppressors. "
01/17/2014 - "Seven of our top hits-including Myh9, which encodes nonmuscle myosin IIa-have not been linked to tumor development, yet tissue-specific Myh9 RNAi and Myh9 knockout trigger invasive SCC formation on tumor-susceptible backgrounds. "
|5.||Muscular Diseases (Myopathy)
06/01/2014 - "In this study, we describe for the first time the clinical and morphological characteristics of recessive myosin IIa myopathy associated with MYH2 missense mutations. "
12/29/2004 - "The E706K mutation in skeletal myosin IIa is associated with a human myopathy. "
01/01/2013 - "Protein aggregates in the form of tubulofilamentous inclusions in association with vacuolated muscle fibers are present at late stage of dominant myosin IIa myopathy and sometimes in Laing distal myopathy. "
|2.||Proteins (Proteins, Gene)
|4.||Myosin Type II
|6.||Small Interfering RNA (siRNA)
|2.||Transcutaneous Electric Nerve Stimulation (TENS)